Eribulin Mesylate Patent Expiration
Eribulin Mesylate is Used for treating patients with metastatic breast cancer. It was first introduced by Eisai Inc
Eribulin Mesylate Patents
Given below is the list of patents protecting Eribulin Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Halaven | US6214865 | Macrocyclic analogs and methods of their use and preparation |
Jun 16, 2019
(Expired) | Eisai Inc |
| Halaven |
US6214865 (Pediatric) | Macrocyclic analogs and methods of their use and preparation |
Jan 20, 2024
(Expired) | Eisai Inc |
| Halaven | US6469182 | Intermediates in the preparation of macrocyclic analogs |
Jun 16, 2019
(Expired) | Eisai Inc |
| Halaven | US7470720 | Methods and compositions for use in treating cancer |
Jun 16, 2019
(Expired) | Eisai Inc |
| Halaven | US8097648 | Methods and compositions for use in treating cancer |
Jan 22, 2021
(Expired) | Eisai Inc |
| Halaven | USRE46965 | Intermediates for the preparation of analogs of Halichondrin B | Jan 08, 2027 | Eisai Inc |
| Halaven |
USRE46965 (Pediatric) | Intermediates for the preparation of analogs of Halichondrin B | Jul 08, 2027 | Eisai Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Eribulin Mesylate Generics
Several generic applications have been filed for Eribulin Mesylate. The first generic version for Eribulin Mesylate was by Gland Pharma Ltd and was approved on Apr 5, 2024. And the latest generic version is by Jiangxi Qingfeng Pharmaceutical Co Ltd and was approved on Jun 28, 2024.
Given below is the list of companies who have filed for Eribulin Mesylate generic.
1. JIANGXI QINGFENG
Jiangxi Qingfeng Pharmaceutical Co Ltd has filed for 1 generic for Eribulin Mesylate. Given below are the details of the strengths of this generic introduced by Jiangxi Qingfeng.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/2ML (0.5MG/ML) | solution | Prescription | INTRAVENOUS | AP | Jun 28, 2024 |
2. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 1 generic for Eribulin Mesylate. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG/2ML (0.5MG/ML) | solution | Prescription | INTRAVENOUS | AP | Apr 5, 2024 |